Bio-Rad Laboratories — Third Quarter 2026 Earnings Summary

Bio-Rad Laboratories reported third-quarter 2026 net sales of $656.4 million, representing a 0.5% increase over the prior year period. The company's net income for the quarter was $458.6 million, driven primarily by a change in the fair market value of its investment in Sartorius AG, while non-GAAP net income was $71.5 million. On a currency-neutral basis, total revenue grew 0.7%, with the Clinical Diagnostics segment increasing 2.8% and the Life Science segment declining 2.4%. For the full year 2026, the company forecasts non-GAAP currency-neutral revenue to range from a 3.0% decline to a 0.5% growth, with an operating margin between 10.0% and 12.0%.